Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jul;72(1):244–248. doi: 10.1038/bjc.1995.310

Hormone replacement treatment and breast cancer risk: a cooperative Italian study.

C La Vecchia 1, E Negri 1, S Franceschi 1, A Favero 1, O Nanni 1, R Filiberti 1, E Conti 1, M Montella 1, A Veronesi 1, M Ferraroni 1, et al.
PMCID: PMC2034162  PMID: 7599060

Abstract

The relationship between hormone replacement treatment (HRT) and breast cancer risk was analysed using data from a case-control study conducted between June 1991 and February 1994 in six Italian centres on 2569 patients aged below 75 with histologically confirmed breast cancer and 2588 controls admitted to hospital for a wide spectrum of acute, non-neoplastic, non hormone-related diseases. Ever HRT use was reported by 7.5% of cases and 7.5% of controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 0.9-1.5]. The risk increased with increasing duration of use: the ORs were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. There was no clear pattern of risk with reference to time since starting use, but the OR was significantly elevated (OR = 2.0, 95% CI 1.3-2.9) for women who had stopped HRT within the last 10 years. No association was observed in those who had stopped HRT more than 10 years ago (OR = 1.0). The increased OR for women who had stopped HRT within the last 10 years was consistent across strata of identified covariates, and was significantly related to duration of use. This study confirms the absence of a strong association between HRT and breast cancer risk, although the risk estimate was above unity for women who had used HRT for 5 years or longer. However, the risk was significantly elevated in the short to medium term after use, particularly for long-term use. This short-term increased risk is consistent with an effect of HRT on one of the later stages of the process of breast carcinogenesis. The flattening of risk with increasing time since stopping, and hence the absence of a long-term cumulative excess in breast cancer risk after stopping HRT exposure, has relevant implications on individual risk assessment and public health.

Full text

PDF
244

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergkvist L., Adami H. O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. doi: 10.1056/NEJM198908033210505. [DOI] [PubMed] [Google Scholar]
  2. Brinton L. A., Hoover R., Fraumeni J. F., Jr Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986 Nov;54(5):825–832. doi: 10.1038/bjc.1986.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brinton L. A., Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 1993;15(1):66–79. doi: 10.1093/oxfordjournals.epirev.a036117. [DOI] [PubMed] [Google Scholar]
  4. Bruzzi P., Negri E., La Vecchia C., Decarli A., Palli D., Parazzini F., Del Turco M. R. Short term increase in risk of breast cancer after full term pregnancy. BMJ. 1988 Oct 29;297(6656):1096–1098. doi: 10.1136/bmj.297.6656.1096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cauley J. A., Gutai J. P., Kuller L. H., LeDonne D., Powell J. G. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989 Jun;129(6):1120–1131. doi: 10.1093/oxfordjournals.aje.a115234. [DOI] [PubMed] [Google Scholar]
  6. Colditz G. A., Stampfer M. J., Willett W. C., Hennekens C. H., Rosner B., Speizer F. E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990 Nov 28;264(20):2648–2653. [PubMed] [Google Scholar]
  7. Colditz G. A., Stampfer M. J., Willett W. C., Hunter D. J., Manson J. E., Hennekens C. H., Rosner B. A., Speizer F. E. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control. 1992 Sep;3(5):433–439. doi: 10.1007/BF00051356. [DOI] [PubMed] [Google Scholar]
  8. Day N. E., Brown C. C. Multistage models and primary prevention of cancer. J Natl Cancer Inst. 1980 Apr;64(4):977–989. [PubMed] [Google Scholar]
  9. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988 Dec 15;42(6):832–838. doi: 10.1002/ijc.2910420606. [DOI] [PubMed] [Google Scholar]
  10. Henderson B. E. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1859–1864. doi: 10.1016/s0002-9378(89)80007-9. [DOI] [PubMed] [Google Scholar]
  11. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987 Jul;94(7):620–635. doi: 10.1111/j.1471-0528.1987.tb03166.x. [DOI] [PubMed] [Google Scholar]
  12. Kaufman D. W., Palmer J. R., de Mouzon J., Rosenberg L., Stolley P. D., Warshauer M. E., Zauber A. G., Shapiro S. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol. 1991 Dec 15;134(12):1375–1401. doi: 10.1093/oxfordjournals.aje.a116041. [DOI] [PubMed] [Google Scholar]
  13. La Vecchia C., Bruzzi P., Boyle P. Some further consideration on the role of oral contraceptives in breast carcinogenesis. Tumori. 1990 Jun 30;76(3):220–224. doi: 10.1177/030089169007600302. [DOI] [PubMed] [Google Scholar]
  14. La Vecchia C., Decarli A., Parazzini F., Gentile A., Liberati C., Franceschi S. Non-contraceptive oestrogens and the risk of breast cancer in women. Int J Cancer. 1986 Dec 15;38(6):853–858. doi: 10.1002/ijc.2910380612. [DOI] [PubMed] [Google Scholar]
  15. La Vecchia C., Franceschi S., Decarli A., Gallus G., Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984 Sep;73(3):667–671. [PubMed] [Google Scholar]
  16. La Vecchia C., Negri E., Franceschi S., Parazzini F. Non-contraceptive oestrogens and breast cancer: an update. Int J Cancer. 1992 Jan 2;50(1):161–162. doi: 10.1002/ijc.2910500131. [DOI] [PubMed] [Google Scholar]
  17. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  18. Mack T. M., Ross R. K. Risks and benefits of long-term treatment with estrogens. Schweiz Med Wochenschr. 1989 Dec 16;119(50):1811–1820. [PubMed] [Google Scholar]
  20. Palmer J. R., Rosenberg L., Clarke E. A., Miller D. R., Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol. 1991 Dec 15;134(12):1386–1401. doi: 10.1093/oxfordjournals.aje.a116042. [DOI] [PubMed] [Google Scholar]
  21. Parazzini F., La Vecchia C., Negri E., Bianchi C., Fedele L. Determinants of estrogen replacement therapy use in northern Italy. Rev Epidemiol Sante Publique. 1993;41(1):53–58. [PubMed] [Google Scholar]
  22. Steinberg K. K., Thacker S. B., Smith S. J., Stroup D. F., Zack M. M., Flanders W. D., Berkelman R. L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991 Apr 17;265(15):1985–1990. [PubMed] [Google Scholar]
  23. Wingo P. A., Layde P. M., Lee N. C., Rubin G., Ory H. W. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987 Jan 9;257(2):209–215. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES